Published in Cancer Res on January 15, 2006
ER chaperones in mammalian development and human diseases. FEBS Lett (2007) 4.40
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther (2008) 1.64
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther (2008) 1.28
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 1.17
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 1.16
Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther (2009) 1.13
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther (2006) 1.09
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther (2007) 1.02
Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther (2010) 0.99
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther (2010) 0.95
Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother (2010) 0.91
Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity. Mol Ther (2010) 0.88
Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Ther (2011) 0.86
Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. J Exp Clin Cancer Res (2011) 0.86
Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model. PLoS One (2009) 0.86
Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model. Cell Mol Immunol (2012) 0.77
DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice. Int J Clin Exp Med (2015) 0.75
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. Cancer Microenviron (2013) 0.75
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med (2000) 6.20
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med (2001) 5.56
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73
Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med (1977) 3.38
Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther (1999) 2.82
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol (2001) 2.22
Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood (2002) 2.02
Down-regulation of the antitumor immune response. Adv Cancer Res (1985) 1.84
Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med (1967) 1.75
Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci U S A (2003) 1.54
Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol (2005) 1.49
Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB. Immunology (1975) 1.46
Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther (2005) 1.38
Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine (2001) 1.36
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol (2003) 1.34
Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J Immunol (2001) 1.31
Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci (2005) 1.31
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther (2003) 1.31
Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol (1999) 1.29
The dual nature of specific immunological activity of tumor-derived gp96 preparations. J Exp Med (1999) 1.27
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther (2004) 1.23
Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood (2002) 1.16
Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner. J Virol (2004) 1.15
Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol (1979) 1.14
Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol (2002) 1.01
Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice. Clin Exp Immunol (1979) 1.00
Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther (2002) 0.99
Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat Med (2001) 0.99
A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res (2003) 0.98
Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res (2004) 0.98
DNA replication of first-generation adenovirus vectors in tumor cells. Hum Gene Ther (2000) 0.97
Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res (2005) 0.96
Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin Exp Immunol (2002) 0.94
Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes. Mol Ther (2001) 0.93
Induction of tolerogenic DCs: 'you are what you eat'. Trends Immunol (2003) 0.93
A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J Virol (2002) 0.91
Macrophages orchestrate the immune response to tumor cell death. Cancer Res (2001) 0.90
Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Hum Gene Ther (1999) 0.86
Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. Cancer Gene Ther (2006) 0.85
Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice. Int Immunopharmacol (2004) 0.84
Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res (2001) 0.83
CD46 is a cellular receptor for group B adenoviruses. Nat Med (2003) 4.35
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 3.19
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 2.67
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity (2009) 2.44
Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med (2002) 2.13
Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol (2012) 2.07
Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol Ther (2007) 1.88
Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol (2004) 1.72
A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol (2006) 1.65
The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther (2003) 1.63
Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med (2004) 1.54
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol (2003) 1.49
Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther (2005) 1.38
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res (2007) 1.32
Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol (2005) 1.31
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One (2008) 1.30
Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res (2002) 1.29
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J Virol (2007) 1.27
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther (2004) 1.23
Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction. Mol Ther (2004) 1.22
Cutting edge: CD83 regulates the development of cellular immunity. J Immunol (2002) 1.21
Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol (2007) 1.20
Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol Ther (2007) 1.18
Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp Hematol (2004) 1.17
Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol (2011) 1.17
Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner. J Virol (2004) 1.15
Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog (2008) 1.13
Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci U S A (2004) 1.11
Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther (2006) 1.09
Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol (2005) 1.09
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res (2011) 1.09
Localization of regions in CD46 that interact with adenovirus. J Virol (2005) 1.08
Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. J Immunol (2005) 1.05
In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J Virol (2008) 1.03
Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin Cancer Res (2012) 1.03
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol (2011) 1.02
Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol (2002) 1.01
A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol (2012) 1.00
Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci U S A (2004) 0.99
Strategies to increase drug penetration in solid tumors. Front Oncol (2013) 0.99
Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res (2004) 0.99
Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther (2010) 0.98
Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res (2002) 0.98
In situ adenovirus vaccination engages T effector cells against cancer. Vaccine (2009) 0.97
A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette. J Virol (2006) 0.97
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood (2009) 0.97
Toward a stem cell gene therapy for breast cancer. Blood (2009) 0.97
Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res (2005) 0.96
Receptor usage of a newly emergent adenovirus type 14. Virology (2009) 0.95
Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res (2007) 0.94
The complete nucleotide sequence, genome organization, and origin of human adenovirus type 11. Virology (2003) 0.94
A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res (2007) 0.92
An adenoviral expression system for AAV rep78 using homologous recombination. Mol Ther (2002) 0.92
A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J Virol (2002) 0.91
Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother (2012) 0.90
Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells. PLoS Pathog (2013) 0.90
Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol (2012) 0.89
Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Curr Opin Mol Ther (2009) 0.88
A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J Virol (2002) 0.87
Identifying functional adenovirus-host interactions using tandem mass spectrometry. Methods Mol Med (2007) 0.85
Structural and functional studies on the interaction of adenovirus fiber knobs and desmoglein 2. J Virol (2013) 0.85
Attenuation of CD4+ T-cell function by human adenovirus type 35 is mediated by the knob protein. J Gen Virol (2012) 0.85
Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. J Virol (2008) 0.83
Inhibition of TGFbeta1 makes nonimmunogenic tumor cells effective for therapeutic vaccination. J Immunother (2009) 0.83